Business Wire

NY-BEHAVOX

20.10.2020 14:02:09 CEST | Business Wire | Press release

Share
Danske Bank Enhances Risk Management After Fast-Paced SaaS Implementation of Behavox Compliance Solution

Behavox , the world’s only AI-based data operating platform used by firms to catch misconduct before it causes massive regulatory fines and company crises, today announced that Danske Bank A/S , Denmark’s largest, full-service bank, has successfully implemented Behavox’s solution in less than five months for compliance supervision.

"Danske Bank is committed to developing innovative solutions to help us reach the highest standards of corporate governance and meet the expectations of our customers, employees and other stakeholders," said Simon Kingsbury, Executive Vice President at Danske Bank. “By partnering with Behavox, we have been able to significantly advance our capabilities in compliance. By using the artificial intelligence and machine learning of Behavox we are able to rapidly identify potentially non-compliant activity and take appropriate action."

Behavox has vast customer experience successfully implementing the largest, most complex projects in the financial services sector – from the world’s biggest multinational banks to the most prominent hedge funds and private equity firms. Danske Bank represents one of the larger projects Behavox has implemented, making the four-month SaaS-based deployment a major achievement for the customer and company alike.

In June, Danske Bank partnered with Behavox to establish group wide compliance communications monitoring, and has since completed a seamless, full SaaS implementation of the Behavox Compliance solution. The Behavox Compliance solution is helping the bank become faster, smarter, and more agile in supporting its employees as they work for the bank’s millions of customers throughout the Nordics and beyond.

“As the future of the workplace is likely to remain increasingly distributed, Danske Bank needs an agile compliance solution that allows them to strengthen regulatory compliance controls in their mission to modernize banking," said Nabeel Ebrahim, Chief Revenue Officer at Behavox. “As one of our largest European customers, Behavox is proud to have delivered a regulatory compliance solution that allows Danske Bank to aggregate, analyze, and act on their entire organization's data to help them uphold their risk management commitments."

The ability for Behavox’s solution to provide multilingual (data privacy compliant) coverage of compliance requirements across numerous voice and text-based applications in multiple markets is critical for Danske Bank as well as other leading international firms. Behavox supports financial regulatory compliance requirements for Dodd-Frank, MAR, FCPA, SMR, and MiFID II, and its solutions meet the requirements of the most demanding global regulators, such as FINRA, CFTC, and FCA.

About Behavox Ltd.

Behavox is the gold standard for enterprise risk and compliance solutions. Its AI-powered technology helps global banks, hedge funds, and private equity firms identify bad actors quickly and accurately, preventing massive fines and company-debilitating crises. Behavox solutions uncover financial regulatory misconduct like insider trading, collusion, and market manipulation as well as HR-related misconduct, such as racism, sexual harassment, and discrimination. As an award-winning team of innovators and industry experts, Behavox has a reputation for successfully implementing the largest, most complex, global projects in the market. Customers rely on Behavox as an indispensable extension of their teams. They depend on Behavox to protect the integrity of their operations and preserve the trust of their clients. Founded in 2014, Behavox is headquartered in New York City and has offices in Montreal, San Francisco, Seattle, Singapore, Tokyo, London, and Abu Dhabi. More information about the company is available at www.behavox.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye